NACOC Licensed · LI 2475 · February 2026
Africa's First
Pharmaceutical-Grade
Cannabis Producer
Hemp Medicinal Farm Ltd is Ghana’s licensed cultivator of pharmaceutical-grade cannabis flower. Built to supply EU and Canadian pharmaceutical markets with documented, traceable, GACP-compliant raw materials.
50,000
kg Annual Pilot Capacity
$133B
Global Market by 2030
0
Prior Licensed Suppliers
in West Africa
LI 2475
NACOC Licensing Framework
Feb 2026
Production Overview
Cultivation Model
Hybrid Indoor / Outdoor
Primary Output
Pharmaceutical-Grade Dried Flower
Target Markets
EU · Canada · Australia · UK
Minimum Order
25 kg per batch
Documentation
Full COA, Batch Records, Regulatory Package
GACP Phase 1
NACOC Licensed
EU-GMP Roadmap
Why HMF
Strategic Advantages No
Other African Producer Has
First-mover positioning under a purpose-built regulatory framework, backed by scientific infrastructure and a team built for pharmaceutical markets.
01
Regulatory First Mover
Ghana’s NACOC Act 1100 and LI 2475 (launched February 2026) created the first formal licensing framework for pharmaceutical cannabis in West Africa. HMF Ltd holds one of the inaugural licences under this framework — a position that cannot be replicated.
02
Equatorial Climate Advantage
Ghana’s equatorial climate enables year-round cultivation cycles impossible in European or Canadian operations. Our hybrid model combines controlled greenhouse precision with natural outdoor conditions — delivering quality and yield at a production cost European suppliers cannot match.
03
Pharmaceutical Precision
We are not a wellness brand that added compliance. We are a pharmaceutical-grade producer from day one. Every protocol — cultivation, post-harvest, documentation, testing — is designed to meet the raw material standards of regulated pharmaceutical supply chains.
04
Scientific Infrastructure
Our dedicated research division (HMF Research, hmfghlab.com) drives continuous improvement in cannabinoid profiling, phenotype stabilisation, and cultivation science — ensuring the batch-to-batch consistency that pharmaceutical buyers require.
05
AI-Augmented Operations
Proprietary LLM-based technology platforms support cultivation scheduling, harvest optimisation, quality data analysis, and regulatory documentation — reducing variance and accelerating compliance readiness compared to manual operations.
06
Scalable to Demand
From a defined pilot capacity of 50,000 kg annually, HMF Ltd operates across extensive landholdings with a multi-year expansion strategy. Partners can plan long-term supply agreements knowing our production infrastructure is designed to scale alongside their volume requirements.
Why HMF
“Pharmaceutical-Grade Cannabis from Africa’s Most Compliant Producer”
First-mover positioning under a purpose-built regulatory framework, backed by scientific infrastructure and a team built for pharmaceutical markets.
Primary Offering
Pharmaceutical-Grade
Dried Cannabis Flower
Specifically cultivated and processed for consistency in cannabinoid and terpene profiles, with full documentation for pharmaceutical manufacturing integration.
Bulk Cannabis Flower — GMP & GACP Compliant
Pharmaceutical Raw Material
Every batch undergoes meticulous curing and drying to preserve optimal therapeutic compounds while meeting pharmaceutical-grade purity requirements. Full batch records, COAs, and regulatory compliance packages included with every shipment.
THC Range
15–28% (up to 30% custom)
CBD Range
0.5–15% (strain dependent)
Moisture Content
<12%
Minimum Order
25 kg per batch
Shelf Life
24 months (per storage spec)
Heavy Metals
Available Medicinal Strains
HMF-Calm
CBD 18%+ · THC <0.3% · EU Compliant
Neurological, anxiety & EU-threshold pharmaceutical formulations
HMF-Balance
CBD 8–12% · THC 8–12% · Equal Ratio
Balanced therapeutic and entourage-effect formulations
HMF-Elevate
THC 22–28% · CBD 0.5–3% · High-THC
High-THC pharmaceutical applications and advanced API production
HMF-Custom
Any profile · THC up to 30%
Fully bespoke cultivar to exact client specifications — any THC:CBD ratio
Credential 01
NACOC Licence
Licensed under Ghana’s Narcotic Control Commission Act 1100 and Licensing Instrument LI 2475, the first formal pharmaceutical cannabis framework in West Africa.
Active — February 2026
Credential 02
GACP Phase 1
Good Agricultural and Collection Practices framework implementation. Standardised operating procedures, controlled environments, documented quality control, and full traceability systems.
Phase 1 Active
Credential 03
EU-GMP Roadmap
Active four-phase programme toward EU Good Manufacturing Practice certification, designed to meet the raw material requirements of EU pharmaceutical manufacturers.
In Development
Credential 04
ALCOA+ Integrity
All data and documentation adheres to ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate — with complete traceability from seed to shipment.
All Batches
Market Context
The Window Is
Still Open
The pharmaceutical cannabis market is expanding rapidly. The suppliers who establish compliant, documented, scalable production in the next 24 months will hold positions that are structurally difficult to displace.
First Mover
Ghana activated its pharmaceutical cannabis licensing framework in February 2026. HMF Ltd is among the inaugural licensees — with no comparable supplier yet operating in West Africa.
Cost Structural Advantage
Ghana’s equatorial climate, available land, and lower operational costs mean HMF Ltd can produce pharmaceutical-grade material at a fraction of the cost of European competitors.
Supply Gap
EU and Canadian pharmaceutical companies are actively seeking compliant, diversified supply chains. African-origin material with proper documentation is an underserved segment with growing demand.
$133B
Global pharmaceutical cannabis market by 2030 (Source: Stratcann / Industry Analysis)
0
Prior licensed pharmaceutical suppliers in West Africa
$2B
EU pharmaceutical cannabis import opportunity annually
Series A
Initial capital secured · Series A open
Ghana, West Africa
Where Pharmaceutical Precision
Meets African Advantage
50,000 kg annual pilot capacity. Equatorial climate. NACOC licensed. Built to supply EU and Canadian pharmaceutical manufacturers.
Partnership Process
A Structured Path to
Supply Confidence
From initial inquiry to first shipment, our partnership process is designed to ensure regulatory alignment and mutual confidence at every stage.
Ready to Explore the Supply Opportunity?
Pharmaceutical buyers, investors, and research institutions are welcome to reach out directly.